This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Cancer				
Cancer	Breast cancer 2 early onset (BRCA2); RAD52 homolog (RAD52)	<i>In vitro</i> studies suggest that inactivating RAD52 could help treat BRCA2-defective tumors. Small hairpin RNA against RAD52 stopped growth of BRCA2-deficient cells but not BRCA2-expressing cells. Cells deficient in both BRCA2 and RAD52 had greater spontaneous and x-ray-induced chromosomal breaks than cells expressing BRCA2 or RAD52. Next steps could include testing RAD52 inhibition in animal models of BRCA2-deficient cancer. SciBX 4(1); doi:10.1038/scibx.2011.7 Published online Jan. 6, 2011	Patent and licensing status unavailable	Feng, Z. <i>et al.</i> <i>Proc. Natl. Acad. Sci. USA</i> ; published online Dec. 6, 2010; doi:10.1073/pnas.1010959107 Contact: Simon N. Powell, Memorial Sloan-Kettering Cancer Center, New York, N.Y. e-mail: powells@mskcc.org